Welcome to our dedicated page for Aquestive Therapeutics news (Ticker: AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics stock.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company that frequently reports on the progress of its proprietary drug delivery technologies and product candidates. Company news often centers on Anaphylm™ (dibutepinephrine) Sublingual Film, a polymer matrix-based epinephrine prodrug product candidate in late-stage development for severe allergic reactions, including anaphylaxis. Press releases describe clinical data, regulatory milestones, and interactions with the U.S. Food and Drug Administration (FDA) and other regulators.
Investors following AQST news can expect updates on the FDA review of the Anaphylm New Drug Application, including communications about advisory committee decisions, review status, and identified deficiencies, as well as the company’s efforts to address regulatory feedback. Aquestive also issues news about its global regulatory strategy for Anaphylm, such as planned and ongoing submissions in Canada, Europe, and the United Kingdom, and feedback from agencies like Health Canada and the European Medicines Agency.
Beyond Anaphylm, Aquestive’s news flow includes developments in its AdrenaVerse™ epinephrine prodrug platform and the AQST‑108 topical gel program for dermatologic conditions, including alopecia areata. The company regularly reports quarterly financial results, outlines its outlook, and discusses manufacturing and royalty-based revenues from licensed products such as Suboxone® Sublingual Film, Sympazan® Oral Film, Ondif® Oral Film, and Azstarys®.
Additional AQST news items cover patent issuances for Anaphylm and related technologies, leadership changes intended to support clinical and commercial execution, participation in healthcare and investor conferences, and financing transactions linked to future product revenues. Readers interested in AQST news can use this page to monitor regulatory, clinical, financial, and strategic announcements that shape the company’s trajectory.
Aquestive Therapeutics (NASDAQ:AQST) has announced plans to monetize anticipated royalties from Sunovion Pharmaceuticals’ FDA-approved apomorphine sublingual film, APL-130277. This product addresses motor fluctuations in Parkinson's disease patients. CEO Keith J. Kendall expressed optimism about generating $50 to $100 million in non-dilutive capital through royalty monetization, which could extend the company's capital runway into 2021. The company had previously granted Sunovion a license for the film, which is a part of its strategy to provide innovative treatment solutions.
Aquestive Therapeutics (NASDAQ: AQST) announced its participation in the 2020 RBC Capital Markets Global Healthcare Conference, scheduled for May 19-20, 2020. The company will present on May 20 at 1:55 PM ET. The presentation will be accessible via a webcast on the company's Investor Relations website, with a replay available for 90 days. Aquestive is focused on innovative drug development, addressing unmet patient needs through their proprietary product pipeline and collaborations. They aim to improve treatment options for CNS conditions and have technologies like PharmFilm® for drug delivery.